LATS2 Inhibits Malignant Behaviors of Glioma Cells via Inactivating YAP
We previously reported that LATS2, the upstream serine/threonine kinase of Yes-associated protein (YAP), is downregulated in gliomas and exhibits negative correlation with the prognosis of glioma patients. In this work, we aimed to explore the role and mechanism of large tumor suppressor kinase (LATS2) in the progression of malignant gliomas. We found that over-expression of LATS2 inhibited glioma cell proliferation and migration/invasion, while LATS2 downregulation promoted them. Mechanistically, LATS2 promoted the phosphorylation of YAP without affecting YAP mRNA expression. Inconsistent with some previous reports, both YAPWT and YAP5SA did not affect the level of LATS2, suggesting that LATS2 did not form a feedback loop with YAP in gliomas. Furthermore, mammalian Ste20-like kinases (MST1) over-expression did not affect the phosphorylation of YAP, suggesting that MST1 may not be the essential upstream serine/threonine kinase of Hippo/YAP pathway in gliomas. Together, LATS2 inhibits glioma cell proliferation and migration/invasion by inactivating YAP.
KeywordsGlioma LATS2 Proliferation Migration/invasion YAP
This study was funded by National Natural Science Foundation of China (No. 81672489; No. 81472345; No. 81872053).
Compliance with Ethical Standards
Glioma tissues diagnosed according to the 2007 World Health Organization classification were collected from Brain Hospital, Affiliated Hospital of Xuzhou Medical University during year 2014–2015. There are 55 cases of glioma samples, including 22 cases of astrocytomas (grade II), 17 cases of anaplastic astrocytomas (grade III), and 16 cases of glioblastomas (grade IV). Eighteen nontumorous brain tissues were obtained from internal decompression of patients with cerebral injury. Written informed consent was obtained from each patient, and the study was approved by the ethics committee of the hospital.
Conflict of Interest
The authors declare that they have no conflict of interest.
- Gao Y, Zhang W, Han X, Li F, Wang X, Wang R, Fang Z, Tong X, Yao S, Li F, Feng Y, Sun Y, Hou Y, Yang Z, Guan K, Chen H, Zhang L, Ji H (2014) YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression. Nat Commun 5(4629)Google Scholar
- Geng J, Sun X, Wang P, Zhang S, Wang X, Wu H, Hong L, Xie C, Li X, Zhao H, Liu Q, Jiang M, Chen Q, Zhang J, Li Y, Song S, Wang HR, Zhou R, Johnson RL, Chien KY, Lin SC, Han J, Avruch J, Chen L, Zhou D (2015) Kinases Mst1 and Mst2 positively regulate phagocytic induction of reactive oxygen species and bactericidal activity. Nat Immunol 16:1142–1152CrossRefGoogle Scholar
- Guo C, Wang X, Liang L (2015) LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis. Int J Clin Exp Pathol 8:1690–1697Google Scholar
- Hergovich A (2016) The roles of NDR protein kinases in Hippo signalling. Genes (Basel) 7Google Scholar
- Park GS, Oh H, Kim M, Kim T, Johnson RL, Irvine KD, Lim DS (2016) An evolutionarily conserved negative feedback mechanism in the hippo pathway reflects functional difference between LATS1 and LATS2. Oncotarget 7:24063–24075Google Scholar
- Zhang X, Ding Z, Mo J, Sang B, Shi Q, Hu J, Xie S, Zhan W, Lu D, Yang M et al (2014) GOLPH3 promotes glioblastoma cell migration and invasion via the mTOR-YB1 pathway in vitro. In: Mol CarcinogGoogle Scholar
- Zhang H, Geng D, Gao J, Qi Y, Shi Y, Wang Y, Jiang Y, Zhang Y, Fu J, Dong Y, Gao S, Yu R, Zhou X (2016) Expression and significance of hippo/YAP signaling in glioma progression. In: Tumour Biol, vol 37, pp 15665–15676Google Scholar
- Zhang C, Wang F, Xie Z, Chen L, Sinkemani A, Yu H, Wang K, Mao L, Wu X (2018) Dysregulation of YAP by the Hippo pathway is involved in intervertebral disc degeneration, cell contact inhibition, and cell senescence. Oncotarget 9:2175–2192Google Scholar
- Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC, Guan KL (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21:2747–2761CrossRefGoogle Scholar
- Zhou X, Xie S, Wu S, Qi Y, Wang Z, Zhang H, Lu D, Wang X, Dong Y, Liu G, Yang D, Shi Q, Bian W, Yu R (2017) Golgi phosphoprotein 3 promotes glioma progression via inhibiting Rab5-mediated endocytosis and degradation of epidermal growth factor receptor. Neuro-Oncology 19:1628–1639CrossRefGoogle Scholar